Log ind
bn_logo_rgb.jpg
Foto: Bavarian Nordic, PR

Bavarian strikes historic Prostvac deal

Top picks in English:

Denmark’s Bavarian Nordic has signed a historic deal with a potential value of almost 1 billion dollars with one of the world’s leading drug companies concerning its prostate cancer drug Prostvac.


BY LONNI LYNGE & BENJAMIN WERNER CHRISTENSEN
Offentliggjort 04.03.15 kl. 14:44

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Onxeo cleared to continue liver cancer study

Judith Greciet - Onxeo.jpg Top picks in English:

French-Danish biotech Onxeo has now received the recommendation to continue an important phase III study with its liver candidate drug Livatag. The first data from the study are expected soon.

Danish hearing aid giants in global showdown

Top picks in English:

The world’s largest hearing device dealer, Amplifon, expresses concern over the entry into the retail market of manufacturers such as William Demant. GN Resound, on the other hand, receives praise and is expected to form even closer ties to its Italian collaborator.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Leo director: New recommendation is an important first step

Top picks in English:

Leo Pharma has won a positive CHMP-recommendation of the biological drug brodalumab – an important milestone in the company’s gamble on biologics “This shows that we take the biological field seriously,” says its R&D chief.

Novo Seeds launches new biotech company

Top picks in English:

Novo Seeds has teamed up with innovation incubator Borean to inject millions in a “very exciting project”, which the investment company was made aware of by an executive at ALK through a third company. Moreover, they have attracted a foreign profile to the role as chairman.

MPI test to give old chemotherapy a new lease on life

Top picks in English:

The Danish company Medical Prognosis Institute has developed a biomarker test that should revitalize a common chemotherapy drug against breast cancer. CEO Peter Buhl Jensen calls it ”the biomarker of the future.”

Forsiden lige nu

Nyt overskud for diagnostikselskab i presset marked

Regnskab.jpg Medico & Rehab:

Trods et generelt prispres på markedet inden for salg af diagnostikudstyr og en sammensmeltning af tre virksomhedskulturer kommer det danske diagnostikselskab Triolab ud af 2016 med et tilfredsstillende resultat, konkluderer direktøren.

Novo Nordisk hives i retten over prisen på Victoza

Medicinal & Biotek:

Novo Nordisk beskyldes for at presse prisen på sin storsælgende GLP-1-analog Victoza i vejret sammen med en amerikansk indkøbsorganisation. Det har nu ført til endnu et massesøgsmål mod den danske koncern.

Lungekræftmiddel godkendt til førstelinjebehandling

Medicinal & Biotek:

De amerikanske sundheds-myndigheder, FDA, har godkendt Zykadia fra Novartis som førstelinjebehandling af særlig type lungekræft.

Cannabisselskab nærmer sig FDA-ansøgning mod epilepsi

Medicinal & Biotek:

Britiske GW Pharmaceuticals er med nye fase 3-data klar til snart at indsende en registreringsansøgning til FDA for et cannabislægemiddel mod en sjælden type epilepsi, der rammer børn.

Onxeo-aktien går amok mandag formiddag

Medicinal & Biotek:

Biotekselskabet Onxeos aktiepris er oppe med mere end 43 pct. på fondsbørsen i København mandag formiddag. Der har ikke været nogen meddelelser fra selskabet.

BMS vil have Opdivo godkendt mod leverkræft

Medicinal & Biotek:

Bristol-Myers Squibb har søgt om at få godkendt sin immunterapi Opdivo til behandling af patienter med leverkræft i USA. Dermed nærmer man sig et marked, som domineres af tyske Bayer, og som det dansk-noterede biotekselskab Onxeo også går efter.

ANNONCE


ANNONCE